EMEA to redefine treatment-resistant depression in light of new approaches in clinical trials
This article was originally published in SRA
Executive Summary
The European Medicines Agency is seeking feedback on how to best define treatment-resistant depression that would help identify an appropriate and homogenous patient population with the condition1.